Morgan Stanley analyst Matthew Harrison downgraded Regeneron Pharma (NASDAQ: REGN) from Overweight to Equalweight with a price target of $767.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE